קיסאנלה - Kisunla
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | N06DX Other anti-dementia drugs |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | תר××× ×××× ×ª ת×××¡× ×××× ×¤××××, CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Kisunla is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimerâs disease (Early symptomatic Alzheimerâs disease) who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers with confirmed amyloid pathology. |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 ××× ×¢××× ×ר××¤× Â |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ק×ס×× ×× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ELI LILLY AND COMPANY, USA |
| ×©× ××¢× ×ר×ש×× | ELI LILLY ISRAEL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2024. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 24/01/2026 |
השינוי האחרון נעשה בֹ־24 בינואר 2026 ב־04:56